Protagonist Therapeutics Price to Free Cash Flow Ratio 2015-2022 | PTGX
Historical price to free cash flow ratio values for Protagonist Therapeutics (PTGX) since 2015.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Protagonist Therapeutics Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2022-07-01 |
7.86 |
|
0.00 |
| 2022-03-31 |
23.68 |
$-2.48 |
0.00 |
| 2021-12-31 |
34.20 |
$-2.35 |
0.00 |
| 2021-09-30 |
17.72 |
$-2.38 |
0.00 |
| 2021-06-30 |
44.88 |
$-2.16 |
0.00 |
| 2021-03-31 |
25.90 |
$-2.20 |
0.00 |
| 2020-12-31 |
20.16 |
$-2.12 |
0.00 |
| 2020-09-30 |
19.55 |
$-2.05 |
0.00 |
| 2020-06-30 |
17.66 |
$-2.22 |
0.00 |
| 2020-03-31 |
7.06 |
$-1.53 |
0.00 |
| 2019-12-31 |
7.05 |
$-1.64 |
0.00 |
| 2019-09-30 |
12.01 |
$-1.54 |
0.00 |
| 2019-06-30 |
12.11 |
$-1.37 |
0.00 |
| 2019-03-31 |
12.57 |
$-2.22 |
0.00 |
| 2018-12-31 |
6.73 |
$-2.26 |
0.00 |
| 2018-09-30 |
10.29 |
$-2.60 |
0.00 |
| 2018-06-30 |
6.72 |
$0.10 |
69.06 |
| 2018-03-31 |
8.59 |
$0.07 |
114.84 |
| 2017-12-31 |
20.80 |
$0.18 |
114.79 |
| 2017-09-30 |
17.67 |
$-1.21 |
0.00 |
| 2017-06-30 |
11.31 |
$-6.03 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.382B |
$0.027B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
